Epizyme Inc (EPZM) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 18 from a previous price target of $20 . Mizuho advised their investors in a research report released on May 10, 2016.
Many Wall Street Analysts have commented on Epizyme Inc. Citigroup Initiated Epizyme Inc on Apr 5, 2016 to “Buy”, Price Target of the shares are set at $17.H.C. Wainwright Upgraded Epizyme Inc on Mar 14, 2016 to ” Buy”, Price Target of the shares are set at $25.Shares were Reiterated by Mizuho on Mar 10, 2016 to “Buy” and Lowered the Price Target to $ 20 from a previous price target of $26 .
Epizyme Inc opened for trading at $8.96 and hit $9.44 on the upside on Friday, eventually ending the session at $9.33, with a gain of 2.87% or 0.26 points. The heightened volatility saw the trading volume jump to 2,34,629 shares. Company has a market cap of $534 M.
In a different news, on Apr 13, 2016, Andrew E. Singer (EVP & CFO) sold 1,013 shares at $12.31 per share price. According to the SEC, on Mar 2, 2016, Peter Tai-ching Ho (Chief Development Officer) purchased 636 shares at $7.47 per share price. On Jan 12, 2016, Carl Goldfischer (director) purchased 555,555 shares at $9.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Epizyme Inc. is a clinical-stage biopharmaceutical company that discovers develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases or HMTs. The Company’s lead product candidate EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling and Phase I MLL-r pediatric patient trial enrolling.